About Retatrutide
Retatrutide is a triple GLP-1, GIP, and glucagon receptor agonist that produced 24.2% weight loss at 48 weeks in the 2023 Phase 2 trial - the highest reported across any weight-loss peptide to date.
Reported benefits
- Drives 24.2% weight loss at 48 weeks (Phase 2)
- Raises resting energy expenditure by 4–6%
- Triggers hepatic lipolysis via glucagon arm
Research citations
- Jastreboff et al. 2023 - NEJM Phase 2
- Rosenstock et al. 2023 - Lancet
How Retatrutide fits the category
Retatrutide sits inside the Best Peptides for Weight Loss category. For the full ranking and head-to-head comparisons, read Best Peptides for Weight Loss.

